Literature DB >> 10837634

Structural and metabolic consequences of liposome-lipoprotein interactions.

.   

Abstract

The two major proposed uses for liposomes, i.e., drug delivery and mobilization of peripheral deposits of cholesterol, each impose requirements and restrictions on liposomal structure, particularly as it affects interactions with lipoproteins. This chapter focuses on the role of lipoproteins and apolipoproteins in (1) disrupting membrane structure and causing the leakage of liposomal contents by inducing disc formation and (2) marking liposomes for whole-particle uptake by receptors involved in lipoprotein metabolism. Control of membrane stability and whole-particle half-life can be achieved by several strategies, such as membrane stiffening, shielding the membrane surface, and increasing the dose or predosing with "empty" liposomes. The rationales and applicabilities of these strategies are discussed in the contexts of liposomes as drug delivery vehicles and as antiatherogenic particles. Directions for further basic and applied research are also presented.

Entities:  

Year:  1998        PMID: 10837634     DOI: 10.1016/s0169-409x(97)00130-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  11 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 3.  Regression of atherosclerosis: insights from animal and clinical studies.

Authors:  Jonathan E Feig
Journal:  Ann Glob Health       Date:  2013-12-25       Impact factor: 2.462

Review 4.  The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Authors:  Jonathan E Feig; Jessica L Feig; George D Dangas
Journal:  Coron Artery Dis       Date:  2016-11       Impact factor: 1.439

5.  Effects of mutations in Aedes aegypti sterol carrier protein-2 on the biological function of the protein.

Authors:  James T Radek; David H Dyer; Que Lan
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

Review 6.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

7.  Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies.

Authors:  Beata Chertok; Matthew J Webber; Marc D Succi; Robert Langer
Journal:  Mol Pharm       Date:  2013-08-26       Impact factor: 4.939

8.  Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions.

Authors:  Long Wang; Chunling Wang; Jiao Jiao; Yuqing Su; Xiaobo Cheng; Zhenjun Huang; Xinrong Liu; Yihui Deng
Journal:  Int J Nanomedicine       Date:  2014-08-04

Review 9.  Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis.

Authors:  Sindhu C Pillai; Ankita Borah; Eden Mariam Jacob; D Sakthi Kumar
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

10.  Interaction between VLDL and phosphatidylcholine liposomes generates new γ-LpE-like particles.

Authors:  Agnieszka Ćwiklińska; Barbara Kortas-Stempak; Anna Gliwińska; Anastasis Pacanis; Agnieszka Kuchta; Małgorzata Wróblewska
Journal:  Lipids       Date:  2014-02       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.